...
首页> 外文期刊>Journal of Clinical Research in Pediatric Endocrinology >Urine Levels of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Children with Type 1 Diabetes Mellitus
【24h】

Urine Levels of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Children with Type 1 Diabetes Mellitus

机译:1型糖尿病患儿尿液中基质金属蛋白酶的水平和金属蛋白酶的组织抑制剂

获取原文
           

摘要

Objective: Histopathological changes in the kidney in type 1 diabetes mellitus (T1DM) begin before detection of microalbuminuria. Therefore, there is interest in finding a better biomarker for the early detection of diabetic kidney injury. The aim of this present study was to determine whether urinary indicators of fibrosis are detectable early in the development of T1DM in children and if they may predict progressive renal injury. Methods: Urinary matrix metalloproteinase 2 and 9 (MMP2 and MMP9), tissue inhibitor of metalloproteinase 1 and 2 (TIMP1 and TIMP2) and transforming growth factor-β1 (TGF-β1) were assessed in 33 patients with T1DM with normal renal functions and in 24 healthy controls. Microalbuminuria was not present in the patient group with the exception of three patients. The results were adjusted to urine creatinine (Cr) and the differences between patients and controls were evaluated. These measurements were repeated after one year and the results were compared with the first year results. Results: Urine MMP2/Cr, MMP9/Cr, TIMP1/Cr, TIMP2/Cr, TGF-β1/Cr were not different between the patient and control groups (p&0.05). There were also no significant differences between the first and second year results for these biomarkers (p&0.05). None of these parameters were correlated with hemoglobin A1c, body mass index and duration of T1DM. Interestingly, all parameters were negatively correlated to age of onset of T1DM (p&0.05). Conclusion: Our findings suggest that urinary biomarkers of fibrosis do not show an increase in diabetic children without microalbuminuria. The results also indicate that the risk of early fibrosis may increase as age of onset of T1DM decreases.
机译:目的:在检测到微量白蛋白尿之前,开始对1型糖尿病(T1DM)的肾脏进行组织病理学改变。因此,有兴趣寻找一种更好的生物标记物,用于糖尿病肾损伤的早期检测。本研究的目的是确定在儿童T1DM发育早期是否可以检测到纤维化尿液指标,以及它们是否可以预测进行性肾损伤。方法:对33例肾功能正常的T1DM患者进行了尿液基质金属蛋白酶2和9(MMP2和MMP9),金属蛋白酶1和2的组织抑制剂(TIMP1和TIMP2)以及转化生长因子β1(TGF-β1)的评估。 24个健康对照。除三名患者外,患者组中无微量白蛋白尿。将结果调整为尿肌酐(Cr),并评估患者与对照组之间的差异。一年后重复进行这些测量,并将结果与​​第一年的结果进行比较。结果:患者和对照组之间的尿MMP2 / Cr,MMP9 / Cr,TIMP1 / Cr,TIMP2 / Cr,TGF-β1/ Cr没有差异(p> 0.05)。这些生物标志物的第一年和第二年结果之间也没有显着差异(p> 0.05)。这些参数均与血红蛋白A1c,体重指数和T1DM持续时间无关。有趣的是,所有参数与T1DM的发病年龄呈负相关(p <0.05)。结论:我们的发现表明,在没有微量蛋白尿的糖尿病儿童中,纤维化的尿液生物标志物未见增加。结果还表明,随着T1DM发病年龄的降低,早期纤维化的风险可能会增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号